Why the study?
The study was conducted to assess plasma NT-proCNP levels in patients with COPD and evaluate its diagnostic value for pulmonary hypertension in this population.
NT-proCNP plasma levels are significantly elevated in COPD patients with pulmonary hypertension and correlate with disease severity markers, suggesting its potential as a diagnostic biomarker.
Should not yet change PH screening in COPD; leaves open NT-proCNP as a biomarker pending prospective validation.
To assess N-Terminal Pro C-Type Natriuretic Peptide (NT-proCNP) plasma levels in patients with chronic obstructive pulmonary disease (COPD) and evaluate of its diagnostic value for pulmonary hypertension (PH) in COPD. According to the range of systolic pulmonary artery pressure (SPAP), the COPD patients were divided into group of patients without PH (SPAP < 40 mmHg, n = 42) and group of patients with PH (SPAP ≥40 mmHg, n = 52). Significant differences in NT-proCNP levels were found in patients with and without PH (3.63 ± 0.95 pg/mL vs. 1.42 ± 0.35 pg/mL, p < 0.001). Statistically significant correlations were shown between NT-proCNP levels and SPAP (r = 0.77, p < 0.001), mMRC dyspnea score (r = 0.42, p = 0.001), CAT score (r = 0.60, p < 0.001), and SpO2 (r = − 0.47, p = 0.001). Pulmonary hypertension in COPD patients was associated with higher plasma NT-proCNP levels.
No takes yet. Share an insight, caveat, or question.
Авдеев et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: